{"slug":"ctdna","tag":"ctdna","variants":["ctdna"],"description":"No description yet","count":7,"kinds":{"person":5,"roadmap":1,"biomarker":1},"related":[{"slug":"colorectal","tag":"colorectal","shared":2},{"slug":"liquid-biopsy","tag":"liquid-biopsy","shared":2},{"slug":"mrd","tag":"mrd","shared":2},{"slug":"adc","tag":"adc","shared":1},{"slug":"biomarker","tag":"biomarker","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"diagnostics","tag":"diagnostics","shared":1},{"slug":"genome-wide","tag":"genome-wide","shared":1},{"slug":"genomics","tag":"genomics","shared":1},{"slug":"mced","tag":"mced","shared":1},{"slug":"resistance","tag":"resistance","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","tldr":"Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery."},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care."},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","tldr":"Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade."},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/","tldr":"Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata."},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/","tldr":"Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests."},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","tldr":"Blood carries fragments of tumour DNA. This roadmap follows the tests that read them, from the first sighting in 1948 to blood tests that now choose a drug, spare chemotherapy, or screen for many cancers at once, and it lists the readouts to watch next."},{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/","tldr":"A ctDNA MRD test looks for the tumour's own mutations in blood after surgery. Detection predicts relapse months before scans, and in 2026 the FDA approved Signatera as the companion test selecting bladder cancer patients for adjuvant atezolizumab."}]}